Letter to Vertex: CF Community Demands Global Access to Trikafta

Cystic fibrosis (CF) patients, family members, and advocates representing thousands of families from over 60 countries have joined forces with Just Treatment and Vertex Save Us to write a letter to Vertex Pharmaceuticals demanding access to life-saving CF medication, Trikafta.

The letter highlights Vertex's staggering profits of $9 billion in 2022 from CF product revenues and a total of $38.5 billion in the 11 years since the first CF drug was approved, as well as Vertex's president, Dr. Kewalramani's, personal compensation of $15.9 million in 2022.

We also highlight the Right to Breathe campaign, launched in February 2023, which calls for legal intervention and flexibilities to help CF patients in countries like South Africa, Brazil, Ukraine, and India access Trikafta. We stress the importance of Vertex dropping patent claims, significantly reducing drug prices, and engaging with governments to facilitate access to their medicines or allowing generic alternatives. The CF community and its supporters have made it clear that they expect Vertex to take immediate action to end the intolerable suffering experienced by thousands of patients around the world.